Sarepta's keenly watched muscle dystrophy drug wins FDA approval

(Reuters) - Sarepta Therapeutics Inc's Duchenne muscular dystrophy drug won approval from the U.S. Food and Drug Administration on Monday, capping months of regulatory uncertainty and pressure from parents and patient advocates to endorse it.